BPC-157 and Anxiety: Can It Help or Harm?

The link between BPC 157 and anxiety is one of the more confusing areas of the peptide industry. Some people claim they got relief after using BPC 157 while others claim it exacerbated their anxiety. Both claims seem honest and neither side has any good scientific basis for their experiences. However, a bunch of animal studies abound showing that BPC 157 affects serotonin and dopamine, which are very important for mood regulation. We pay attention to this research and conflicting observations of users and try to explain why both kinds of reaction to BPC are scientifically justified. For a more comprehensive view of the side effects of BPC, visit our BPC-157 risks overview.

BPC-157 and Anxiety - Calming or Concerning?

Conflicting Reports from Users

We have monitored reports of BPC 157 as it relates to anxiety across various forums, subreddits and emails for more than one year. The responses could be split into two groups. The first group noted a significant calming effect: reduced baseline apprehension, increased tolerance to stress and better ability to sleep. The second group, on the contrary, noted few adverse effects: feelings of anxiety, restless behavior, anxiousness or racing thoughts especially after starting use of the drug.

Both groups have provided sincere reports but the lack of blinding, dosing verification, and purity testing renders it impossible to draw any conclusions from their observations. So although they provide evidence that there's such a thing as mood change, they don't tell us anything about what causes it, or if BPC-157 is responsible for this change. The animal experiments bring in the mechanistic explanation that lets one conceive both results as feasible.

The Dopaminergic System Connection

BPC-157 and Dopamine Receptors in Animal Models

One of the most explored neurological effects of BPC-157 is its connection with the dopamine system in animals. According to a 2004 study, BPC-157 influences dopaminergic activity within the brains of rats, having an effect on the functioning of the dopamine receptor system and so making alterations to the behavior dependent on the introduction of dopamine-altering medication.

Dopamine should not be referred to simply as a neurotransmitter that causes a pleasant feeling. Its functions include motivation, reward, attention, as well as evaluation of threats. Insufficient dopaminergic activity is said to lead to apathy and depression while excessive activity is associated with anxiety, psychosis and hypervigilance in specific areas of the brain. A substance capable of affecting dopaminergic activity might so bring about a calming effect in one person while being anxiogenic for another, depending on the individual's activity at the beginning.

Serotonin System Interactions

BPC-157 also interacts with the serotonergic system. A study on BPC-157 and the serotonin system demonstrated that the peptide modulated serotonin-related behaviors in rats, again in a stabilizing rather than unidirectional fashion. Serotonin plays a central role in mood regulation, and most modern antidepressant and anti-anxiety medications target serotonergic pathways.

Interacting with the dopamine and serotonin systems implies that BPC-157 affects the two neurotransmitter systems closely linked with anxiety disorders. This is why the changing effects of BPC-157 on mood could be both positive and negative. Someone with low levels of serotonin or dopamine may behave rather differently than someone with high levels of these neurotransmitters. No studies on either animals or humans have been carried out to determine the extent of this individual variability.

Animal Behavior Studies

Forced Swim Test Results

The forced swim test is widely used as one of the standard tests in preclinical research of depression behavior of rodents. Rats, submerged in water, would stop swimming after sometime and would float without any effort to swim. If a substance reduces this immobility period, it is considered to possess antidepressant properties. A number of research studies found that BPC-157 was capable of reducing immobility in this test, which has been interpreted as antidepressant action. A review of BPC-157 research cited these behavioral results as part of other effects of the peptide in the field of neurology.

The forced swimming test comes with some limitations. It assesses behavioral despair in animals instead of clinical depression in humans. Some researchers raised an issue regarding whether reduced immobility is a marker for a real improvement in mood or just an increase in the movement. But the findings are consistent between studies as well as with the neurotransmitter results.

Elevated Plus Maze Data

The elevated plus maze is commonly used for testing anxiety-like behavior in animals. In this test, the animals are placed on a platform in the shape of a plus sign that has two open and enclosed arms. Anxious animals prefer to stay in the enclosed arms. Animals injected with BPC-157 spent more time in the open arms indicating lower levels of anxiety-like behavior. This result has been confirmed in other studies.

The animal findings, together with the results from their forced swim experiments, indicate that BPC-157 seems to exhibit anxiety-reducing and anti-depressive effects on rats. However, the human experience is more complicated because human stories differ from animal data. The reason is that animals were tested in controlled conditions in their laboratory while the humans brought into the research are pre-conditioned by their existing neurochemistry and present conditions such as the drugs they were using, impurities of the product(s), and/or mental predispositions.

User-Reported Anxiety Changes

Reports of Reduced Anxiety

Those who report an anxiety-reducing effect often do so within days after beginning to take BPC-157. Some say it feels like having "a calmer brain," or being "less prone to stress," even having "stopped thinking too much before sleep." Some say that sleep has improved which contributes to reduced anxiety levels. Others report an active calming effect but emphasize that it is different than drowsiness. This is true for those who take it for healing purposes and consider the positive mood change as just an additional benefit of the drug.

Reports of Increased Anxiety

The contrary viewpoint speaks of onset in the first 1 to 3 days too. Terms such as "wired but tired", "increased awareness of the heart", and "racing mind" are found in such descriptions. Numerous individuals report experiencing a certain amount of physical restlessness related to the peptide rather than an anxiety disorder. A handful of people say that their anxiety vanished by the end of week one, while others have quit due to the anxiety.

Possible Explanations for Both

There are various reasons for the discrepancy. The first reason is personalized neurochemistry: those with low dopamine activity may react differently to dopamine modulation when compared to those with high dopamine activity. Secondly, variability in the product can influence the outcomes: unregulated peptide products come with different levels of impurities and compositions, besides which the contaminating peptides have their own respective impacts. Third, there is the matter of expectation: the placebo or nocebo effect is an important variable when relying on self-reported mood states. In addition to this, the use of concurrent substances: the presence of caffeine, stimulants and anti-depressants may distort or amplify the effects of BPC-157. For further details about drugs, check out the sections of our drug interactions page.